Roche’s $50B Gamble: Tariffs, Jobs, and Pharma’s Future

Mace | 22nd April 2025 | Uncategorised

Swiss pharmaceutical giant Roche plans a $50 billion U.S. investment over five years, creating 12,000 jobs and building new facilities. Driven by Trump-era tariffs, it aims to protect market access, bolster U.S. exports, and adapt to supply chain challenges. The move reflects shifting pharmaceutical strategies amidst global trade tensions.

Swiss pharmaceutical giant Roche has unveiled plans to invest an eye-watering $50 billion (£40.3 billion) into the United States over the next five years, signalling a clear response to the mounting pressure of tariffs imposed by President Donald Trump’s administration. The investment, one of the largest by any foreign pharmaceutical company in recent years, is expected to generate over 12,000 jobs across key sectors such as manufacturing, research and construction. This bold move is being interpreted as a defensive measure to protect Roche’s foothold in the lucrative U.S. market amid increasing trade tensions between Switzerland and Washington. Central to this announcement is the establishment of state-of-the-art facilities dedicated to the production of gene therapy treatments, continuous glucose monitors, and weight-loss medicines. Roche’s forthcoming factory in Pennsylvania will focus on advanced gene therapy, potentially transforming how chronic illnesses are treated. Meanwhile, ...

Subscribe to The Mace

Join the member community shaping British politics and stay ahead of what's really happening in the world of politics and public affairs, with expert analysis, breaking news, and insider insights from Westminster and Brussels. The Mace is the leading news source and resource for the government affairs industry, offering required reading and lobby intelligence for professionals.

To see what you are missing out on by not subscribing to The Mace, click here to download our full membership info-pack. This includes having no paywall on op-ed content or profiles/interviews, allowing professional profiles to be read with maximum impact and visibility by government, special advisers, MPs, peers, civil servants, and policy and political decision-makers.

UK Budget 2026: How does Healey plan to help young people?

Ella Beadman | October 30, 2026

Healey’s 2026 Budget offers some support for young people through apprenticeships, entrepreneurship and home ownership, but with more policies yet to be revealed, much remains uncertain.

We need to talk about Kemi

Mace | October 5, 2026

In contrast to last year's Tory conference, Kemi Badenoch is coming out guns blazing, not the least when it comes to defence, says Flora Watkins

Markus Leutert, Corporate Affairs, PerkinElmer – “Focus on outcomes, rather than outputs”

Mace | September 29, 2026

Leutert's career has included moments close to politics, including time as a speechwriter, but he concluded that he can have more impact behind the scenes.

Leader in UK Public Affairs: Dr Michelle Howard, Senior Advisor for Defence and Space, Lexington Communications: “The future of public affairs is full of promise for the creative”

Mace | September 16, 2026

Lexington’s Michelle Howard explains how an unconventional career spanning opera, journalism, hydropower and defence led her into public affairs, why political instability rewards creativity and listening, and what

FGS Global acquires Washington government affairs agency

Mace | August 7, 2026

FGS Global has acquired Washington, DC-based government affairs firm Rich Feuer Anderson.

Kemi’s true blue purge, with help from Sir Philip May

William Cash | July 26, 2026

The news that former Home Secretary Sir Grant Shapps has failed to make the new Tory candidate list has put fear into dozens of former Conservative MPs. Whether